Aquinox Pharmaceuticals Inc. (AQXP) 10.00 $AQXP
Inflammatory Bowel Disease - Pipeline Review, H1 2014: 73 Companies and 135 Drugs Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/rmqbbx/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - ASKA Pharmaceutical Co., Ltd. - ActogeniX NV - Addex Therapeutics - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - AlbireoPharma - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Antibe Therapeutics, Inc. - Aquinox Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Athersys, Inc. - Atlantic Healthcare Limited - Axxam SpA - Basilea Pharmaceutica AG - BioLineRx, Ltd. - Biotec Pharmacon ASA - Boehringer Ingelheim GmbH - Catabasis Pharmaceuticals, Inc. - Celsus Therapeutics Plc - ChironWells GmbH - Complix NV - Compugen Ltd. - Creabilis SA - Delenex Therapeutics AG - Eisai Co., Ltd. - Emergent BioSolutions Inc. - Ensemble Discovery Corporation For more information visit http://www.researchandmarkets.com/research/rm...flammatory
Aquinox Pharmaceuticals Announces Closing of Initial Public Offering
GlobeNewswire - Wed Mar 12, 11:58AM CDT
Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP) announced today the closing of its initial public offering of 4,830,000 shares of its common stock at a public offering price of $11.00, which included 630,000 shares issued upon the exercise in full of the underwriters' option to purchase additional shares. All of the shares of common stock were offered by Aquinox. The aggregate offering price was $53.1 million, before underwriting discounts, commissions and estimated expenses. The net proceeds from the sale of the shares, after deducting the underwriting discounts, commissions and other estimated offering expenses, will be approximately $47.0 million.
Coupons.com IPO A Hot Ticket, Soars 88% On First Day
at Investor's Business Daily - Fri Mar 07, 11:24AM CST
Coupons.com (COUP) cashed in a winning ticket Friday with an initial public offering that nearly doubled on its first day of trading. The website provider of digital coupons priced at $16, above the proposed range of $12 to $14. The stock opened at...
Aquinox Pharmaceuticals Prices Initial Public Offering
GlobeNewswire - Fri Mar 07, 9:23AM CST
Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $11.00 per share for an aggregate offering of $46.2 million, before underwriting discounts, commissions and estimated expenses. All of the shares of common stock are being offered by Aquinox. The Company's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading today under the ticker symbol "AQXP". In addition, Aquinox has granted the underwriters a 30-day option to purchase up to 630,000 additional shares of common stock at the offering price. The offering is expected to close on March 12, 2014, subject to customary closing conditions.
Inflammatory Bowel Disease - Pipeline Review, H1 2014: 73 Companies and 135 Drugs Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/rmqbbx/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - ASKA Pharmaceutical Co., Ltd. - ActogeniX NV - Addex Therapeutics - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - AlbireoPharma - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Antibe Therapeutics, Inc. - Aquinox Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Athersys, Inc. - Atlantic Healthcare Limited - Axxam SpA - Basilea Pharmaceutica AG - BioLineRx, Ltd. - Biotec Pharmacon ASA - Boehringer Ingelheim GmbH - Catabasis Pharmaceuticals, Inc. - Celsus Therapeutics Plc - ChironWells GmbH - Complix NV - Compugen Ltd. - Creabilis SA - Delenex Therapeutics AG - Eisai Co., Ltd. - Emergent BioSolutions Inc. - Ensemble Discovery Corporation For more information visit http://www.researchandmarkets.com/research/rm...flammatory
Aquinox Pharmaceuticals Announces Closing of Initial Public Offering
GlobeNewswire - Wed Mar 12, 11:58AM CDT
Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP) announced today the closing of its initial public offering of 4,830,000 shares of its common stock at a public offering price of $11.00, which included 630,000 shares issued upon the exercise in full of the underwriters' option to purchase additional shares. All of the shares of common stock were offered by Aquinox. The aggregate offering price was $53.1 million, before underwriting discounts, commissions and estimated expenses. The net proceeds from the sale of the shares, after deducting the underwriting discounts, commissions and other estimated offering expenses, will be approximately $47.0 million.
Coupons.com IPO A Hot Ticket, Soars 88% On First Day
at Investor's Business Daily - Fri Mar 07, 11:24AM CST
Coupons.com (COUP) cashed in a winning ticket Friday with an initial public offering that nearly doubled on its first day of trading. The website provider of digital coupons priced at $16, above the proposed range of $12 to $14. The stock opened at...
Aquinox Pharmaceuticals Prices Initial Public Offering
GlobeNewswire - Fri Mar 07, 9:23AM CST
Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $11.00 per share for an aggregate offering of $46.2 million, before underwriting discounts, commissions and estimated expenses. All of the shares of common stock are being offered by Aquinox. The Company's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading today under the ticker symbol "AQXP". In addition, Aquinox has granted the underwriters a 30-day option to purchase up to 630,000 additional shares of common stock at the offering price. The offering is expected to close on March 12, 2014, subject to customary closing conditions.
